NSE filing, NSE: AMBANIORGO. Summary written from the filing by ALFA Finder's alert engine.
Ambani Orgochem Ltd: key numbers
- Share price
- ₹155.05
- Market cap
- ₹116.9 Cr
- Revenue (annual)
- ₹240.7 Cr
- Net profit (annual)
- ₹1.33 Cr
- P/E (TTM)
- 87.6×Sector 34.5×
- Promoter holding
- 52.59%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ambani Orgochem Ltd
All →Ambani Orgochem Convertible Warrants
Ambani Orgochem members approved a Rs 43.93 Crore preferential warrant issue and capital changes. Promoters receive 30.1 lakh of the 43.93 lakh warrants.
- Value
- ₹43.93 Cr
Ambani Orgochem Investor Presentation: Key Takeaways
H1 FY27 consolidated: revenue ₹171.22 cr (+54.87%), EBITDA ₹11.32 cr (+43.00%), PAT ₹3.45 cr vs ₹0.19 cr. Strategy: capacity expansion and downstream specialty chemicals.
Ambani Orgochem Annual General Meeting
Ambani Orgochem's 1st EGM on 26 October 2026 took up four special resolutions. Items cover authorised capital, the capital clause, and preferential warrants.
Ambani Orgochem Convertible Warrants
Ambani Orgochem issued a corrigendum to its EGM notice, reducing the proposed preferential issue size of convertible warrants to Rs. 43.925 Crore following allotment revisions.
- Value
- ₹43.92 Cr
Ambani Orgochem Convertible Warrants
Ambani Orgochem reduced its proposed preferential issue of convertible warrants by Rs. 0.25 Crore, following the removal of one allottee. The revised issue size is Rs. 43.925 Crore.
- Value
- ₹43.92 Cr
Ambani Orgochem Annual General Meeting
Ambani Orgochem Limited seeks shareholder approval at an EGM to issue 43.95 lakh convertible warrants at Rs. 100 each, raising Rs. 43.95 Crore.
- Value
- ₹43.95 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.